Order before Dec 15th and benefit from our end of the year specials in CNS models for disease-modifying properties demonstration (MT03).
Inquire about our neurodegenerative diseases human models for Alzheimer’s and Huntington’s diseases. Don’t forget to mention our promotional offer code “MT03″.
Order before Dec 15th and benefit from our end of the year specials in safety (MT02).
Inquire about our mitochondrial liabilities & mitochondrial behavior offers for your safety needs. Don’t forget to mention our promotional offer code “MT02″.
ICDD will attend the Tea and health meeting in Berlin on Oct 27-28th. Come & discuss with us the opportunities that our expertise & know-how on the measure of functionally integrated mitochondrial outcomes can deliver to your research, proving marketing allegations on your products.
ICDD will be present on Oct 20th-21st, at Targeting Mitochondria 2012. This year, the meeting focus is on Sirtuins and Medicine for tomorrow: The promising Target.
Meet us at our booth and come listen to our oral presentation summarizing our results. We explored the effects of resveratrol, a Sirtuin activator, on mitochondrial functions in relation to ageing & age-related diseases.
ICDD is actively seeking partnering with biotech/pharma companies and venture groups to fulfill its mission: enhance the efficiency in the drug development process. Come meet with us at booth# 2505 to discover our technologies tuned toward:
- better anticipation of toxicity at a pre-clinical stage leading to significant cost-avoidance and improved productivity in the drug development chain of value
- identification and development of companion diagnostic in Alzheimer’ disease and other neurodegenerative disease
- discovery of novel biomarkers associated with drug tolerance in anti-viral medicine
Our experts will answer your needs whether you’re considering developing a drug targeting the mitochondria or are seeking to gain confidence in mechanisms and confidence in safety to accompany your product development.
Our technologies will be showcased during the fast track session on June 27th from noon to 6pm at The St. Regis hôtel, Washington, D.C. / 923 16th Street & K Street NW
The European Pharmacog Consortium, a pre-competitive collaborative project, to which ICDD is a partner in identifying novel biological markers indicator of conversion from mild cognitive impairment to Alzheimer’s disease, is a keynote opening at the drug discovery summit on June 7th in Philadelphia during the world pharmaceutical congress.
ICDD scientists present posters and an oral presentation on the company’s latest technological development in Berlin for the 1st World Congress on Targeting Mitochondria the 18th and 19th of November 2010.
We will welcome you at our booth on this occasion.
Pharmacog aims at identifying a research tool matrix capable of accelerating drug development in Alzheimer’s disease (AD) in order to better show clinical efficacy of disease-modifying drugs. Upon completion the project will generate tools to better define the therapeutic potential of each drug candidate, markers to select potential responders to these drugs and diagnostic markers to follow the drug’s efficacy with respect to disease progression allowing the gain better and faster insight in the clinical efficacy of drugs during clinical trials and speed approval of pertinent drugs in AD.
The unique know-how of ICDD in the discovery and validation of biomarkers using the patented Promembrane® technology® will participate in the success of the Pharmacog project studying the impact of the inflammatory processes and their regulation in AD progression. “AD is a key area of development for ICDD; we are committed to the development of more pertinent stratification markers identifying more accurately prodromal stages of the disease to enhance therapeutic interventions while it is still possible” says Nathalie Compagnone CEO of ICDD. Our participation in the program validates the interest of our technology in identifying markers essential to therapeutic developments that give scientists and clinicians a better understanding of when and how the pertinent therapeutic interventions can occur.
You are aware that 30-40% of previouly unrecognized toxicity is due to drug-induced mitochondrial impairement. You want to identify early mitochondrial liabilities. We offer the Mitosafe® bioenergetic screen, a novel and highly sensitive assay, faster and cheaper than the current state of the art methodology.
You want to reduce drug attrition by encovering flags for human clinical tolerance at the pre-clinical stage. Ask information about our system biology mitostream® platform. A fully integrated technology trained to identify potential for ADRs in your chemical series, rank-order compounds, derisking clinical development.
Developing drugs for neurodegenerative diseases ? We are introducing the Mitoselect® technology, a secondary screening to identify disease modifying drugs in Alzheimer’s disease, Huntington’s disease or Ageing.
Come see us at the French BioTour in Philadelphia, sept 13-14 or at BioPharm 2010 in Boston, Sept15-17.